Special Issue

Recent Advances in Inhalation Therapy

Message from the Guest Editors

In recent years, the pharmaceutical technology field has witnessed remarkable improvements, revolutionizing the approaches to and administration of drugs for respiratory conditions. The benefits of inhalation therapy include non-invasiveness, rapid onset, reduced local metabolic enzymes and localized drug delivery. The goal of this Special Issue is to collect the most recent advancements and cutting-edge discoveries in the field of inhalation therapy. These include, but are not limited to, the development of specific formulations for delivery to the lungs, investigations on the pulmonary drug delivery process and pulmonary deposition in vitro, in silico and in vivo, and the creation of innovative inhaler devices. Moreover, studies focused on advanced delivery strategies for drugs and biopharmaceuticals, such as the use of nanotechnology (nanosuspensions, liposomes and others nanocarriers) and inhalable microparticles, are highly welcomed. This Special Issue will include original research and thematic reviews on any aspects related to the above-mentioned topics. Expert opinions on clinical translation and speculative hypotheses on debated topics are also invited.

Guest Editors

Dr. Luca Casula

Unit of Drug Sciences, Department of Life and Environmental Sciences, University of Cagliari, 09124 Cagliari, Italy

Dr. Francesco Lai

Department of Life and Environmental Sciences, University of Cagliari, 09124 Cagliari, Italy

Deadline for manuscript submissions

closed (25 September 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/198535

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

